Tata India Pharma & Healthcare Fund-Regular Plan-Growth
₹31.2287
₹0.54 (-1.71%)
NAV as of 29 May 2026
Today's NAV — all variants
Regular · Growth
₹₹31.2287
₹0.54 (-1.71%)
29 May 2026
AMFI: 135812
Direct · Growth
₹₹36.7782
₹0.64 (-1.70%)
29 May 2026
AMFI: 135810
Regular · IDCW
₹₹30.0340
₹0.52 (-1.71%)
29 May 2026
AMFI: 135811
Direct · IDCW
₹₹35.5828
₹0.62 (-1.70%)
29 May 2026
AMFI: 135807
Returns (Lumpsum)
CAGR for periods ≥ 1 yearSIP Returns (XIRR)
₹1,000/month SIP, annualisedSIP since inception — what ₹100/month became
Real NAV backtest from day one
₹12,500
Invested
₹29,882
Value today
15.9%
XIRR (p.a.)
₹100/month SIP from fund inception · Current value as of today
Try SIP Calculator with this fund's history₹5,000 lumpsum at launch — value today
Invested on the fund's first NAV date
₹5,000
Invested
₹15,614
Value today
11.6%
CAGR (p.a.)
One-time investment at fund inception · Growth purely from NAV appreciation
Try Lumpsum Calculator₹10L corpus with ₹5,000/month withdrawals since inception
Corpus is still growing despite monthly payouts
₹10,00,000
Initial corpus
₹6,25,000
Withdrawn
₹16,28,791
Corpus left
+₹12,53,791 net gain — withdrew ₹6,25,000 AND corpus grew
Plan your SWP with real NAV₹6L corpus via 12-month STP from a liquid fund at inception
₹50K/month transferred from HDFC Liquid → this fund at launch
₹6,00,000
Invested
₹19,94,884
Value today
+6.5%
vs lumpsum
STP beat direct lumpsum by 6.5% — reduced timing risk paid off
Model your own STP with real NAVBeat the benchmark — ₹100/month SIP
Same SIP in this fund vs the benchmark index
This fund
₹29,882
Benchmark
₹26,350
+₹3,532 extra wealth vs the benchmark index
Backtest this SIP yourself₹1 lakh on the worst crash day — 22 Mar 2020
Worst single-day Nifty drop during this fund's life
₹1,00,000
Invested
₹3,77,500
Value today
3.8×
Multiple
Staying invested through that crash turned ₹1L into ₹3,77,500 — a 3.8× return
Read: Staying invested through crashesDirect vs Regular — ₹500/month over 10 years
Expense ratio drag on your actual returns
Direct plan
₹1,57,357
Regular plan
₹1,43,033
Direct earns ₹14,324 more on a ₹60K investment — 2.39% extra return per year
Same fund, same NAV history — only the expense ratio differs. Direct plans always outperform Regular over time.
Learn about Direct vs Regular plansFund Details
Risk Metrics
Trailing 1 year, annualised-0.14
Sharpe Ratio
+0.01
Alpha
0.35
Beta
-0.13
Sortino
14.21%
Std Dev
-16.99%
Max Drawdown
Portfolio Holdings
Top 50 holdings · as of Mar 2026
| Security | % NAV |
|---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD INE044A01036 | 10.34% |
SUN PHARMACEUTICAL INDUSTRIES LTD INE044A01036 | 9.87% |
DIVI LABORATORIES LTD INE361B01024 | 5.92% |
ABBOTT INDIA LTD INE358A01014 | 5.89% |
DIVI LABORATORIES LTD INE361B01024 | 5.83% |
HEALTHCARE GLOBAL ENTERPRISES LTD INE075I01017 | 5.45% |
HEALTHCARE GLOBAL ENTERPRISES LTD INE075I01017 | 5.39% |
ABBOTT INDIA LTD INE358A01014 | 5.37% |
MAX HEALTHCARE INSTITUTE LTD INE027H01010 | 5.17% |
MAX HEALTHCARE INSTITUTE LTD INE027H01010 | 5.14% |
CIPLA LTD INE059A01026 | 5.10% |
CIPLA LTD INE059A01026 | 5.07% |
APOLLO HOSPITALS ENTERPRISE LTD INE437A01024 | 4.25% |
RAINBOW CHILDRENS MEDICARE LTD INE961O01016 | 4.23% |
RAINBOW CHILDRENS MEDICARE LTD INE961O01016 | 4.23% |
APOLLO HOSPITALS ENTERPRISE LTD INE437A01024 | 4.06% |
MANKIND PHARMA LTD INE634S01028 | 3.73% |
DR REDDYS LABORATORIES LTD INE089A01031 | 3.73% |
MANKIND PHARMA LTD INE634S01028 | 3.57% |
FORTIS HEALTHCARE LTD INE061F01013 | 3.55% |
BAYER CROPSCIENCE LTD INE462A01022 | 3.51% |
DR REDDYS LABORATORIES LTD INE089A01031 | 3.45% |
BAYER CROPSCIENCE LTD INE462A01022 | 3.34% |
LUPIN LTD INE326A01037 | 3.18% |
FORTIS HEALTHCARE LTD INE061F01013 | 3.17% |
METROPOLIS HEALTHCARE LTD INE112L01020 | 3.07% |
METROPOLIS HEALTHCARE LTD INE112L01020 | 3.02% |
SYNGENE INTERNATIONAL LTD INE398R01022 | 2.94% |
LUPIN LTD INE326A01037 | 2.94% |
DR. LAL PATH LABS LTD INE600L01024 | 2.69% |
SYNGENE INTERNATIONAL LTD INE398R01022 | 2.64% |
SAI LIFE SCIENCES LTD INE570L01029 | 2.63% |
DR. LAL PATH LABS LTD INE600L01024 | 2.60% |
SAI LIFE SCIENCES LTD INE570L01029 | 2.58% |
ALKEM LABORATORIES LTD INE540L01014 | 2.49% |
ALKEM LABORATORIES LTD INE540L01014 | 2.45% |
GLAXOSMITHKLINE PHARMACEUTICALS LTD INE159A01016 | 2.44% |
NEULAND LABORATORIES LTD INE794A01010 | 2.41% |
J.B.CHEMICALS & PHARMACEUTICALS LTD INE572A01036 | 2.40% |
J.B.CHEMICALS & PHARMACEUTICALS LTD INE572A01036 | 2.21% |
GLOBAL HEALTH LTD INE474Q01031 | 2.16% |
GLAXOSMITHKLINE PHARMACEUTICALS LTD INE159A01016 | 2.14% |
NEULAND LABORATORIES LTD INE794A01010 | 2.08% |
AJANTA PHARMA LTD INE031B01049 | 2.04% |
GLOBAL HEALTH LTD INE474Q01031 | 2.01% |
FDC LTD INE258B01022 | 1.94% |
AJANTA PHARMA LTD INE031B01049 | 1.90% |
FDC LTD INE258B01022 | 1.84% |
VIJAYA DIAGNOSTIC CENTRE LTD INE043W01024 | 1.72% |
SANOFI INDIA LTD INE058A01010 | 1.70% |
Performance Comparison
Interested in This Fund?
Our experts will help you decide if this fund fits your goals.
Compare with Similar Funds
Investment Objective
Tata India Pharma & Healthcare Fund-Regular Plan-Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Tata India Pharma & Healthcare Fund-Regular Plan-Growth is a Sectoral / Thematic mutual fund offered by Tata Mutual Fund. The fund has been operational for over 10 years. It manages assets worth ₹1,278 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE Healthcare. The current expense ratio is 2.11%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations